FindTrial
Sign In

Effect of Taurine in treatment of diabetes

The effects of taurine supplementation on serum levels of endothelial markers, metabolic parameters, adipokines, inflammatory and glycemic indicators and nutritional status in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180712040438N3
Enrollment
120
Registered
2020-02-26
Start date
2020-01-31
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Intervention group: Patients in this group will receive 3 capsules of 1000 milligrams of taurine (product by karen Co. and made in The Iran) for 8 weeks a day. Inte

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with Type 2 Diabetes Patients who use glucose lowering oral medications are well controlled by their blood glucose levels. Body mass index 35-25 kg /m 2 will be included in the study. age range from 30-60 years

Exclusion criteria

Exclusion criteria: Use of multi-vitamin and mineral supplements over the past 3 months. Taking corticosteroids and non-steroidal anti-inflammatory drugs. Taking insulin Patients with polycystic ovary syndrome Patients with chronic diseases such as cardiovascular, renal and hepatic disorders, and hypothyroidism and hyperthyroidism Having certain physiological conditions such as pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
Serum level of Plasminogen activator inhibitor (PAL). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of Tissue plasminogen activator ( tPA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Endothelial markers (ICAM, VCAM). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Level of Adiponektin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of hs-CRP. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of IL-6. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of MM9,3. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of Visfastin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of Glycemic index. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of Leptien. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.;Serum level of Total antioxidant capacity. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement via ELISA kit.—

Secondary

MeasureTime frame
EGFR Assessment of the health-related quality of life (HRQOL). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Via HRQOL questionnaire.;Assessment of the Estimated Glomerular Filtration Rate (eGFR). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Using serum creatinine level.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJalal Moludi

Kermanshah University of Medical Sciences

moludij@tbzmed.ac.ir+98 41 3335 2148

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026